Human trial / meta-analysis — Includes human trial or meta-analysis evidence.
Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.
Auto-discovered from 1 recent study; not yet curated.
What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.
6 published studies by what they were done in. Lab and animal findings often do not carry over to people.
The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.
Tracking 6 published studies of Gemcitabine: 2 in humans, 4 reviews/other.
Reported direction across studies: 2 positive, 1 mixed, 1 negative, 2 inconclusive.
Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.
These counts summarize what the studies reported; they are not a measure of whether Gemcitabine works.
Cancers named in these studies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Jul 2025 · randomized, open-label, phase III, multicenter
This randomized phase III trial assigned 571 patients with unresectable locally advanced pancreatic adenocarcinoma to gemcitabine/nab-paclitaxel with or without Tumor Treating Fields (TTFields). Adding TTFields significantly prolonged median overall survival (16.2 vs 14.2 months; HR 0.82; P = .039), and also improved pain-free survival and distant progression-free survival; PFS, local PFS, and overall response rate were not improved. Device-related skin adverse events occurred in 76.3% of patients (mostly mild-to-moderate) with 7.7% reporting grade 3 skin AEs.
Reported effects: median OS 16.2 mo [15–18], n=571 · OS HR 0.82 [0.68–0.99], p=0.039, n=571 · +6 more
Studied with: gemcitabine/nab-paclitaxel.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed
Redox biology · Nov 2024 · randomized 1:1 controlled trial
This randomized trial compared standard gemcitabine plus nab-paclitaxel chemotherapy with or without high-dose intravenous vitamin C (75 g three times weekly) in patients with metastatic pancreatic cancer. Adding pharmacological ascorbate increased median overall survival (16 vs 8.3 months) and median progression-free survival (6.2 vs 3.9 months) and did not increase adverse events or worsen quality of life. The trial randomized 36 patients (34 received assigned treatment).
Reported effects: median overall survival 16 mo · HR overall survival 0.46 [0.23–0.92], p=0.03 · +3 more
Studied with: gemcitabine + nab-paclitaxel.
Randomized clinical trial testing high-dose intravenous vitamin C added to first-line chemotherapy in metastatic pancreatic cancer with overall and progression-free survival endpoints.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
The Journal of international medical research · Sep 2024 · case report
This is a case report of a woman in her late 50s diagnosed with primary ovarian leiomyosarcoma who underwent surgery. One month after surgery she received gemcitabine plus docetaxel chemotherapy for six months. Recurrence in the pelvic cavity was detected eight months after surgery. The report aims to raise awareness of this rare disease.
Reported effects: chemotherapy_duration 6 mo, n=1 · time_to_recurrence 8 mo, n=1
Studied with: gemcitabine + docetaxel.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Revista colombiana de obstetricia y ginecologia · Jun 2024 · expert consensus / practice guideline based on literature review
This paper is an expert consensus, not a clinical study of a single drug. Eleven specialists reviewed the literature and issued recommendations for managing advanced or metastatic high-grade epithelial ovarian cancer, including surgery, chemotherapy, genetic testing, bevacizumab, and PARP inhibitors. It does not report new patient outcomes from a trial. The document mainly summarizes what the panel suggested based on existing guidelines and evidence.
Studied with: platinum-based chemotherapy, bevacizumab, paclitaxel, carboplatin.
Provides management recommendations for advanced/metastatic epithelial ovarian cancer, including several anticancer agents and maintenance strategies.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Cancers · Apr 2021 · Review
This review summarizes treatment strategies for ovarian clear cell carcinoma (OCCC), a subtype of ovarian cancer that is often resistant to conventional platinum chemotherapy and more common in Asian populations. The authors note frequent deleterious ARID1A/SWI/SNF mutations in OCCC and propose three therapeutic approaches: prioritizing gemcitabine-based chemotherapy, exploiting synthetic lethal vulnerabilities due to SWI/SNF deficiency, and using immune checkpoint blockade given high mutational burden. They suggest ARID1A deficiency could serve as a biomarker to guide precision treatment, but the abstract does not present new experimental or trial data.
AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text
Current opinion in oncology · Jul 1998
This is a narrative review summarizing recent advances in pancreatic cancer. It states that helical CT is increasingly used for staging, the role of chemoradiation in pre- and postoperative settings is being defined, and gemcitabine has become first-line therapy for advanced pancreatic adenocarcinoma. The authors note that growing knowledge of the molecular biology of pancreatic cancer may improve diagnosis, staging, and treatment in the future.
Studied with: radiation therapy.
AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed
The latest additions to Gemcitabine's evidence base, and anything that's been retracted.
Recently addedWhere at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.
A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.
Includes human trial or meta-analysis evidence.
Largest credible effect: median OS 16.2 mo [15–18], n=571 PMID 40448572 · median-survival values 13.9–16.2 across 3 studies
Most authoritative study: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Includes human trial or meta-analysis evidence.
Largest credible effect: median OS 16.2 mo [15–18], n=571 PMID 40448572 · median-survival values 13.9–16.2 across 3 studies
Most authoritative study: Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Includes human trial or meta-analysis evidence.
Largest credible effect: HR overall survival 0.46 [0.23–0.92], p=0.03 PMID 39369582 · median-survival values 6.2–16 across 2 studies
Most authoritative study: A randomized trial of pharmacological ascorbate, gemcitabine, and nab-paclitaxel for metastatic pancreatic cancer
No primary experimental studies yet.
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
No primary experimental studies yet.
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
No primary experimental studies yet.
Most authoritative study: Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
No primary experimental studies yet.
Most authoritative study: Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
No primary experimental studies yet.
Most authoritative study: Treatment Strategies for ARID1A-Deficient Ovarian Clear Cell Carcinoma
No primary experimental studies yet.
Most authoritative study: Expert consensus: Profiling and management of advanced or metastatic epithelial ovarian cancer
No primary experimental studies yet.
Largest credible effect: chemotherapy_duration 6 mo, n=1 PMID 39286855 · effect sizes 6–8 across 2 studies
Most authoritative study: Primary ovarian leiomyosarcoma: a case report
17 ongoing · 46 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.